Posts
Est. 2026 · Pennsylvania
The Discard
The Organs That Could Have Saved Lives — and Didn't
Between 20 and 29 percent of recovered deceased-donor kidneys are discarded rather than transplanted. Not lost in transit. Not medically unusable. Discarded — after recovery, after preservation, after offer — because no transplant center accepted them in time. The discard is not a failure of supply. It is a failure of the architecture that governs what happens to the supply after it arrives.
When an OPO recovers a kidney from a deceased donor, the organ enters the allocation system. The UNOS algorithm generates a ranked list of potential recipients — patients whose blood type, HLA compatibility, geographic location, and medical scores make them candidates for this particular organ. The list is offered sequentially: the transplant center caring for the top-ranked patient receives the offer first. The center reviews the organ's characteristics — age, medical history, KDPI score, biopsy results if taken — and accepts or declines.
If the center declines, the offer moves to the next center on the list. And the next. And the next. Each declination takes time — hours, in many cases — during which the organ is in preservation solution, accumulating cold ischemia time. Each additional hour of cold ischemia degrades the organ's viability and reduces its likelihood of functioning well after transplant. By the time an organ has worked through twenty or thirty declinations, it may have accumulated enough ischemia time that the centers near the bottom of the list face a choice between a marginal organ and no organ. Some accept. Some decline. Some organs expire before a willing center is reached.
This is the offer chain. It is the mechanism through which a recovered organ can become a discarded organ — not through any single malicious or negligent decision, but through the sequential accumulation of individually rational declinations that collectively produce an irrational outcome.
A recovered kidney that no center accepts is not a failed organ. It is a failure of the system that governs the offer. The organ was viable when it left the donor. It became unviable in transit through the architecture.
The composite offer chain above is not exceptional. Senate investigators and academic researchers have documented cases involving dozens of offer declinations before a kidney is accepted or discarded. Each declination has a documented reason — most of them individually defensible. The aggregate outcome is indefensible: a viable organ recovered from a donor whose family consented to donation is destroyed because the architecture through which it was offered is not designed to prevent that outcome.
The Kidney Donor Profile Index, introduced in 2014, scores donor kidneys on a scale of 1 to 100 — low scores indicating lower-risk, higher-quality kidneys; high scores indicating older donors with more comorbidities. The system was designed to improve allocation efficiency by matching kidney quality to recipient prognosis. Low-KDPI kidneys would go to recipients with the best expected long-term outcomes; high-KDPI kidneys would be more broadly available.
In practice, KDPI has become the primary driver of discard. Acceptance rates for kidneys fall sharply as KDPI rises — not because the medical evidence supports wholesale rejection of high-KDPI kidneys, but because the score provides transplant centers with a legible shortcut for a decision that is, in reality, much more nuanced. A KDPI of 85 does not mean the kidney is not worth transplanting. For many dialysis patients, a KDPI 85 kidney transplant is still significantly better than continued dialysis. But the score reads as high risk, and high risk interacts with center outcome metrics in a way that makes declination rational from the center's perspective even when acceptance would be better for the patient.
The discard problem is, at its core, an incentive problem. Transplant centers are publicly evaluated on their one-year patient and graft survival rates. These metrics are reported on the SRTR website, reviewed by CMS, and used by patients choosing centers. A center that accepts marginal organs — high-KDPI kidneys, older livers, organs from donors with complex medical histories — will have lower reported survival rates than a center that declines the same organs. The center with lower reported rates risks regulatory review, adverse publicity, and patient selection shifts.
The rational center strategy — rational from the perspective of institutional self-protection — is to be selective. Accept the clean, low-risk organs. Decline the marginal ones. Let another center deal with the offer chain. If no center accepts, the organ is discarded. The discard does not appear in any center's outcome metrics. The patient on the waitlist who might have received that organ dies on dialysis. That death also does not appear in any center's outcome metrics, because the patient was never that center's patient.
The matrix reveals the perversity precisely. From a center's institutional perspective, the dominant strategy is conservative acceptance — take clean organs, decline marginal ones. Graft failures hurt you. Declinations don't. Patient deaths while waiting don't appear in your data at all. The system measures what happens to the patients you treat, not what happens to the patients you declined to treat. The patients who die in the gap are statistically invisible.
The center incentive architecture is not aligned with what the clinical evidence actually shows about high-KDPI kidneys. Multiple studies have found that for most end-stage renal disease patients, transplanting a high-KDPI kidney — even one that will not function as long as a low-KDPI kidney — is superior to remaining on dialysis, measured by both life expectancy and quality of life. A KDPI 85 kidney that functions for five years gives a patient five years off dialysis. That five years is likely to extend their overall survival relative to five years on dialysis, even if the kidney eventually fails.
Punch biopsies of donor kidneys — a procedure in which a core of kidney tissue is removed and analyzed for the degree of fibrosis, glomerulosclerosis, and other signs of chronic damage — are performed on a significant proportion of recovered kidneys, particularly higher-KDPI organs. The stated purpose is to provide centers with additional information about organ quality. The operational effect, in many cases, is to add cold ischemia time and generate an additional reason to decline.
Biopsy results are interpreted by pathologists, and the interpretation is not standardized. The same biopsy result may lead one center to accept and another to decline. The procedure takes time — hours, in some cases — during which the organ is accumulating ischemia. And the predictive value of kidney biopsies for post-transplant outcomes is, in the research literature, contested: biopsies have shown limited ability to predict whether a kidney will function well after transplant. Yet their use is widespread, and their results are used as grounds for declination in offer chains that are already accumulating ischemia with each passing hour.
The discard rate is the single most damning number in the organ transplant system. It is not the number of patients who die on the waitlist — those deaths can be attributed to scarcity, to the gap between donors and recipients that no allocation system can fully close. The discard rate is the number of organs that were recovered — that families consented to donate, that OPOs retrieved, that entered the allocation system as viable — and were not used.
Every discarded kidney represents at least one family that said yes at the worst moment of their lives and whose consent produced nothing. It represents at least one patient on the waitlist who was not transplanted that day. It represents the system's failure to convert the supply it already had into the outcome it exists to produce.
The discard is not primarily a medical failure. It is an architectural one. The incentive structure rewards center selectivity. The scoring system amplifies risk aversion. The offer chain accumulates ischemia time with every declination. The biopsy protocol adds uncertainty and delay. The system was not designed to minimize discard. It was designed to maximize center autonomy — and center autonomy, when exercised through the lens of institutional self-protection rather than patient welfare, produces a discard rate that peer countries do not approach.
The discard is where the conversion layer — the process that takes a recovered organ and produces a transplant — fails most visibly. The algorithm generates the offer list. The centers execute the accept/decline decisions. The accumulating ischemia is the clock that cannot be stopped. Each of these elements is separately governed and separately optimized: the algorithm by UNOS policy, the center decisions by institutional metrics, the ischemia clock by logistics infrastructure. No single actor is responsible for the aggregate discard rate. The architecture is designed so that no single actor can be. The invisible patient — the one who dies on dialysis because a viable organ traveled through 15 declinations and expired — has no representation in any of the metrics that govern any of the decisions that produced their outcome. They are the system's most complete blind spot.
Next · Post V · The Board — Who governed UNOS. Transplant professionals self-regulating. Member fees funding the regulator. The conflict of interest as structural feature.
